- Home
- LOCO vs ERAS Comparison
LOCO vs ERAS Comparison
Compare LOCO & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- ERAS
- Stock Information
- Founded
- LOCO 1980
- ERAS 2018
- Country
- LOCO United States
- ERAS United States
- Employees
- LOCO N/A
- ERAS N/A
- Industry
- LOCO Restaurants
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- LOCO Consumer Discretionary
- ERAS Health Care
- Exchange
- LOCO Nasdaq
- ERAS Nasdaq
- Market Cap
- LOCO 331.5M
- ERAS 348.4M
- IPO Year
- LOCO 2014
- ERAS 2021
- Fundamental
- Price
- LOCO $10.96
- ERAS $1.45
- Analyst Decision
- LOCO Buy
- ERAS Strong Buy
- Analyst Count
- LOCO 3
- ERAS 6
- Target Price
- LOCO $15.50
- ERAS $4.83
- AVG Volume (30 Days)
- LOCO 347.2K
- ERAS 1.2M
- Earning Date
- LOCO 07-31-2025
- ERAS 08-11-2025
- Dividend Yield
- LOCO N/A
- ERAS N/A
- EPS Growth
- LOCO 6.54
- ERAS N/A
- EPS
- LOCO 0.86
- ERAS N/A
- Revenue
- LOCO $476,032,000.00
- ERAS N/A
- Revenue This Year
- LOCO $6.28
- ERAS N/A
- Revenue Next Year
- LOCO $1.14
- ERAS N/A
- P/E Ratio
- LOCO $12.99
- ERAS N/A
- Revenue Growth
- LOCO 1.22
- ERAS N/A
- 52 Week Low
- LOCO $8.29
- ERAS $1.01
- 52 Week High
- LOCO $14.25
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- LOCO 57.24
- ERAS 52.19
- Support Level
- LOCO $10.94
- ERAS $1.38
- Resistance Level
- LOCO $11.55
- ERAS $1.58
- Average True Range (ATR)
- LOCO 0.40
- ERAS 0.11
- MACD
- LOCO -0.02
- ERAS 0.01
- Stochastic Oscillator
- LOCO 67.74
- ERAS 64.86
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.